Skip to content

A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism

A Randomized Double-Blind Sham-Controlled Trial To Evaluate The Treatment Efficacy of Magnetic Resonant Therapy in Autistic Disorder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01985308
Enrollment
28
Registered
2013-11-15
Start date
2013-11-30
Completion date
2014-04-30
Last updated
2024-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Brief summary

The purpose of this study is to show that a magnetic field applied to the front part of the brain of children suffering from Autism Spectrum Disorder(ASD) can improve function and ameliorate symptoms.

Interventions

DEVICEMagnetic Resonance Therapy (MRT)-Active
DEVICEMagnetic Resonance Therapy (MRT)-Sham

Sponsors

Wave Neuroscience
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
4 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Primary diagnosis of Autism Spectrum Disorder by Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) rendered by the examination and sufficient Childhood Autism Rating Scale 2nd Edition (CARS-2) score to qualify as autism. * CARS-2 score between 36 and 47 inclusively * Age between 4 and 12 years (at day of informed consent) * Child must suffer disrupted sleep patterns defined as a minimum of 3 nights per week of delayed onset of sleep or night-time awakenings. If these are medicated with mild sedatives or melatonin and corrected, the requirement for medication or melatonin will qualify as evidence of a sleep disorder.

Exclusion criteria

* Diagnosis of Asperger's Disorder, Pervasive Developmental Disorder Not Otherwise specified * History of clinically significant traumatic brain injury * Any condition associated with increased intracranial pressure * Cerebral Aneurysm * Down's Syndrome or other chromosomal abnormality * EEG abnormalities that indicate seizure risk * Intracranial implant * Unstable medical condition not otherwise specified * Clinically significant organic disease unrelated to autism

Design outcomes

Primary

MeasureTime frameDescription
Childhood Autism Rating Scale 2nd Edition (CARS2)5 WeeksThe Childhood Autism Rating Scale is a behavior rating scale that measures the severity of autism symptoms in children. It consists of 15 sub-domains including relating to people, adaptation to change, verbal communication, and visual response. Each sub-domain is rated between 1-4, with the total score ranging from a low of 15 to a high of 60. Scores below 30 indicate that the individual is in the non-autistic range. Scores between 30 and 36.5 indicate mild to moderate autism, and scores from 37 to 60 indicate severe autism. A higher CARS score represents more severe symptoms. In the present study, the primary outcome was numerical change in CARS score between baseline and Week 5 (end of the double-blind portion of the study). The comparison of the mean and standard deviation between groups is reported. Difference in CARS score between the baseline and week 5 (end of double-blind portion of the study). CARS value at 5 weeks minus CARS value at baseline.

Countries

United States

Participant flow

Participants by arm

ArmCount
MRT-Active
Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks. MRT-Active
14
MRT-SHAM
Magnetic field is not active, but a sham coil is used, for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks. MRT-SHAM
14
Total28

Baseline characteristics

CharacteristicMRT-ActiveMRT-SHAMTotal
Age, Categorical
<=18 years
14 Participants14 Participants28 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous7.26 years
STANDARD_DEVIATION 2.53
7.64 years
STANDARD_DEVIATION 2.4
7.45 years
STANDARD_DEVIATION 2.43
Race/Ethnicity, Customized
African-American
1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Asian/Pacific Islander
5 Participants1 Participants6 Participants
Race/Ethnicity, Customized
Caucasian
8 Participants11 Participants19 Participants
Race/Ethnicity, Customized
Hispanic
0 Participants2 Participants2 Participants
Sex: Female, Male
Female
4 Participants1 Participants5 Participants
Sex: Female, Male
Male
10 Participants13 Participants23 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 140 / 14
other
Total, other adverse events
3 / 143 / 14
serious
Total, serious adverse events
0 / 140 / 14

Outcome results

Primary

Childhood Autism Rating Scale 2nd Edition (CARS2)

The Childhood Autism Rating Scale is a behavior rating scale that measures the severity of autism symptoms in children. It consists of 15 sub-domains including relating to people, adaptation to change, verbal communication, and visual response. Each sub-domain is rated between 1-4, with the total score ranging from a low of 15 to a high of 60. Scores below 30 indicate that the individual is in the non-autistic range. Scores between 30 and 36.5 indicate mild to moderate autism, and scores from 37 to 60 indicate severe autism. A higher CARS score represents more severe symptoms. In the present study, the primary outcome was numerical change in CARS score between baseline and Week 5 (end of the double-blind portion of the study). The comparison of the mean and standard deviation between groups is reported. Difference in CARS score between the baseline and week 5 (end of double-blind portion of the study). CARS value at 5 weeks minus CARS value at baseline.

Time frame: 5 Weeks

Population: Children diagnosed with Autism Spectrum Disorder

ArmMeasureValue (MEAN)Dispersion
MRT-ActiveChildhood Autism Rating Scale 2nd Edition (CARS2)-7.68 units on a scaleStandard Deviation 4.56
MRT-SHAMChildhood Autism Rating Scale 2nd Edition (CARS2)-1.61 units on a scaleStandard Deviation 2.37
p-value: 0.0002t-test, 2 sided
Post Hoc

Child Autism Rating Scale Subdomain Item 11 (Verbal Communication) - Percent of Subjects Who Improved

Child Autism Rating Scale 2nd Edition (CARS2) consists of 15 Subdomains to rate a child's behavior, characteristics, and abilities against the expected developmental growth of a typical child. This outcome provides the percent of subjects who improved between baseline and Week 10 following all active treatment.

Time frame: Baseline until after Week 10

Population: Children diagnosed with Autism Spectrum Disorder

ArmMeasureValue (NUMBER)
MRT-ActiveChild Autism Rating Scale Subdomain Item 11 (Verbal Communication) - Percent of Subjects Who Improved66.0 Percentage who improved
Post Hoc

Child Autism Rating Scale Subdomain Item 7 (Visual Response) - Percent of Subjects Who Improved

Child Autism Rating Scale 2nd Edition (CARS2) consists of 15 Subdomains to rate a child's behavior, characteristics, and abilities against the expected developmental growth of a typical child. This outcome provides the percent of subjects who improved between baseline and Week 10 following all active treatment.

Time frame: Baseline until after Week 10

Population: Children diagnosed with Autism Spectrum Disorder

ArmMeasureValue (NUMBER)
MRT-ActiveChild Autism Rating Scale Subdomain Item 7 (Visual Response) - Percent of Subjects Who Improved71.4 percentage who improved

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026